The corporate owned a 15% stake in immunotherapy developer Lyell, which recently raised $493m, with a fair value of $203m as of the end of 2019.

Shiratronics added $3m from Breakout Ventures to a LivaNova-backed round that will support clinical development of its neuromodulation-based migraine treatment.

Takeda Ventures and Alexandria Venture Investments contributed to the $15.5m first close of the gene therapy developer's series A round.

Roche Venture Fund returned to help SutroVax, a developer of vaccines for a range of deadly infectious diseases, push its overall funding past $280m.

Tepco Power Grid helped the specialised care software developer take its latest round, which already included Line, Mixi, Aioi Nissay Dowa, Akatsuki, Global Kids and Konica Minolta, to $14.3m.

UT Southwestern spinout Recode Therapeutics has completed an oversubscribed $80m series A round featuring Osage University Partners.

Illumina was among the returning investors for the round that will help Columbia spinout Kallyope prepare a weight loss treatment for clinical trials.

Illumina Ventures was among the returning investors for the round that will help Kallyope prepare a weight loss treatment for clinical trials.

Duke University, North Carolina State University and UNC-Chapel Hill grew their cumulative spinout tally year-on-year but are set for challenging times ahead.

Viva Biotech contributed to a round that will help Regenacy Pharmaceuticals push its diabetic peripheral neuropathy candidate into phase 2 trials.